Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe

AIDS

Volumn 18, Issue 10, 2004, Pages 1443-1451

  Thorne, Claire ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Children; HAART; Highly active antiretroviral therapy; Hypercholesterolaemia; Hypertriglyceridaemia; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; FAT; GLUCOSE; LIPID; STAVUDINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BODY FAT; CHILD; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LABORATORY TEST; LIPID METABOLISM; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; PATIENT INFORMATION; PRIORITY JOURNAL; SEROPREVALENCE; SEX DIFFERENCE;

ADIPOSE TISSUE; ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERLIPIDEMIAS; RISK FACTORS;

EID: 3142707107     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131334.38172.01     Document Type: Article

References (46)

1. Carr A, Samaras K, Thorsidottir A, Kaufman GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellilus: a cohort study. Lancet 1999, 353:2093-2099.
2. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Adda N, Rozenbaum W, et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabet Metab 1999, 25:383-392.
3. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13:2493-2505.
4. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001, 6:9-20.
5. Chen DS, Misra A, Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002, 87:4845-4856.
6. Leow MK, Addy CL, Mantzoros CS. Clinical review 159. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003, 88:1961-1976.
7. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003, 361:726-735.
8. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003, 33:571-576.
9. Brambilla P, Sala N, Renzetti F, Manzoni P, Vanzulli A, Chiumello G, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001, 15:2415-2422.
10. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000, 14:2123-2128.
11. Arpadi SM, Cuff PA, Horlick MN, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4 lymphocyte count and CD4 lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 2001, 27:30-34.
12. Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ, et al. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pedlatr Infect Dis J 2003, 22:463-465.
13. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002, 21:405-410.
14. Vigano A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003, 32:482-489.
15. Cheseaux JJ, Jotterand V, Aebi C, Gnehm H, Kind C, Nadal D, et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr 2002, 30:288-293.
16. Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS 2003, 17:1319-1327.
17. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001, 15:761-770.
18. European Collaborative Study. Are there gender and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr 2003, 33:635-641.
19. Kind C, Rudin C, Siegrist C-A, Wyler CA, Biedermann K, Lauper LJ, et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS 1998, 12:205-210.
20. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998, 12:F241-F247.
21. de Martino M, Tovo P-A, Balducci M, Galli L, Gabiano C, Rezza G, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000, 284:190-197.
22. Gabiano C, Tovo P-A, de Martino M, Galli L, Giaquinto C, Loy A, et al. Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission. Pediatr 1992, 90:369-374.
23. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994, 43: 1-10.
24. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001, 357:592-598.
25. Centers For Disease Control and Prevention. 2000 CDC Growth Charts: United States. Atlanta, GA: National Center for Health Statistics; 2003.
26. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002, 16:2447-2454.
27. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25-F32.
28. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr 2002, 30:440-447.
29. Heath KV, Hogg RS, Chan KJ, Harris MA, Montessori V, O'Shaughnessy MV, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001, 15:231-239.
30. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003, 32:48-56.
31. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ, Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. .AIDS 2001, 15: 1389-1398.
32. Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002, 3:49-55.
33. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002, 31:50-55.
34. Galli M, Veglia F, Angarano G, Santambrogio S, Meneghini E, Gritti F, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003, 34:58-61.
35. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) 2003, 82:129-146.
36. Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 2002, 110:e56.
37. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors, the Swiss HIV Cohort Study. Circulation 1999, 100:700-705.
38. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001, 15:725-734.
39. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.
40. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003, 4:1-10.
41. European Collaborative Study. Management of vertically HIV-infected children in Europe. Acta Paediatr 2003, 92:246-250.
42. McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 2003, 111:e275-e281.
43. van d, V, Reiss P. Lipid profiles associated with antiretroviral drug choices. Curr Opin Infect Dis 2003, 16:19-23.
44. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000, 56:1423-1430.
45. World Health Organization. Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: World Health Organization; 2003.
46. Noble S, Goa KL. Amprenavir: a review of its clinical potential in patients with HIV infection. Drugs 2000, 60:1383-1410.